De Souza

Biography

Dr. De Souza joined the team as a Chairman & CEO at nLife on April 19, 2016. He has been president and CEO at leading biopharmaceutical companies, including Biodel Inc., Archemix Corp., and Synaptic Pharmaceuticals. He was co-founder and chief scientific officer at Neurocrine Biosciences, senior vice president and U.S. site head of drug innovation and approval (R&D) at Aventis and director of CNS disease research at DuPont Merck. He serves or has served on the faculty of major U.S. universities, editorial boards, National Institutes of Health committees and boards of directors. He has raised capital in private and public environments and established multiple collaborations with large pharmaceutical companies. nLife Therapeutics has developed a proprietary oligonucleotide delivery platform with strong IP protection. In addition to managing and chairing the board of directors at nLife,he will liaise with investors and management to develop and implement strategy, scientific direction and fundraising.

Research Interest

brain-endocrine-immune responses, Neurochemistry, Psychoneuroendocrinology, Neuropsychopharmacology, Neurocrine Biosciences, central nervous system (CNS) and neuromuscular (NS) disorders